$GLUE insider trading
Over the last 12 months, Monte Rosa Therapeutics insiders reported no purchases and 30 sales totaling $3.9M across SEC Form 4 filings. 57% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $3.9M 30 events
- Events · 12m
- 30 Form 4 filings, grouped
- Insiders · 12m
- 7 distinct reporters
- 10b5-1 share
- 57% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | Warmuth MarkusPresident & CEO · O·D | ▼ Sale | 9,500 | $23.18 | $220K | -1.6% | — |
| Jul 15, 2026 | Champoux JenniferChief Operating Officer · O | ▼ Sale | 4,351 | $23.38 | $102K | -6.5% | plan |
| Jul 6, 2026 | Townson SharonChief Scientific Officer · O | ▼ Sale | 6,000 | $23.31 | $140K | -8.1% | plan · 2 tranches |
| Jun 30, 2026 | Janku FilipChief Medical Officer · O | ▼ Sale | 5,407 | $24.5 | $132K | -8.2% | plan |
| Jun 29, 2026 | Janku FilipChief Medical Officer · O | ▼ Sale | 6,000 | $22.95 | $138K | -9.1% | plan |
| Jun 29, 2026 | Manning Anthony M.D | ▼ Sale | 10,000 | $23.11 | $231K | -100% | — |
| Jun 24, 2026 | Janku FilipChief Medical Officer · O | ▼ Sale | 41,845 | $21.08 | $882K | -41.1% | plan · 2 tranches |
| Jun 23, 2026 | Champoux JenniferChief Operating Officer · O | ▼ Sale | 2,175 | $20 | $44K | -3.4% | plan |
| Jun 23, 2026 | Townson SharonChief Scientific Officer · O | ▼ Sale | 3,000 | $20 | $60K | -4.2% | plan |
| Jun 17, 2026 | Champoux JenniferChief Operating Officer · O | ▼ Sale | 2,176 | $19 | $41K | -3.4% | plan |
| Jun 17, 2026 | Townson SharonChief Scientific Officer · O | ▼ Sale | 3,000 | $19 | $57K | -4.2% | plan |
| Jun 1, 2026 | Warmuth MarkusPresident & CEO · O·D | ▼ Sale | 468 | $19.73 | $9K | -0.1% | plan |
| Jun 1, 2026 | Warmuth MarkusPresident & CEO · O·D | ▼ Sale | 4,998 | $19.41 | $97K | -0.8% | plan |
| May 29, 2026 | Townson SharonChief Scientific Officer · O | ▼ Sale | 6,000 | $19.87 | $119K | -8.1% | plan |
| May 27, 2026 | Champoux JenniferChief Operating Officer · O | ▼ Sale | 2,175 | $20 | $44K | -3.4% | plan |
| May 22, 2026 | Champoux JenniferChief Operating Officer · O | ▼ Sale | 2,176 | $19 | $41K | -3.4% | plan |
| May 1, 2026 | Warmuth MarkusPresident & CEO · O·D | ▼ Sale | 5,467 | $18.92 | $103K | -0.9% | plan |
| Apr 14, 2026 | Warmuth MarkusPresident & CEO · O·D | ▼ Sale | 8,000 | $17.64 | $141K | -1.3% | — |
| Apr 9, 2026 | Nickson PhilipChief Business & Legal Officer · O | ▼ Sale | 5,845 | $17.69 | $103K | -9.6% | — |
| Mar 4, 2026 | Dunn EdmundPrincipal Accounting Officer · O | ▼ Sale | 139 | $17.96 | $2K | -0.6% | — |
| Mar 2, 2026 | Warmuth MarkusPresident & CEO · O·D | ▼ Sale | 5,466 | $17.92 | $98K | -0.9% | plan |
| Mar 2, 2026 | Dunn EdmundPrincipal Accounting Officer · O | ▼ Sale | 25,700 | $18.09 | $465K | -53.1% | 2 tranches |
| Feb 23, 2026 | Janku FilipChief Medical Officer · O | ▼ Sale | 9,189 | $19.5 | $179K | -12.2% | — |
| Jan 7, 2026 | Warmuth MarkusPresident & CEO · O·D | ▼ Sale | 5,466 | $23.49 | $128K | -0.9% | plan · 3 tranches |
| Jan 5, 2026 | Nickson PhilipChief Business & Legal Officer · O | ▼ Sale | 3,155 | $15.17 | $48K | -4.9% | — |
| Jan 5, 2026 | Champoux JenniferChief Operating Officer · O | ▼ Sale | 2,629 | $15.17 | $40K | -4% | — |
| Jan 5, 2026 | Dunn EdmundPrincipal Accounting Officer · O | ▼ Sale | 1,039 | $15.17 | $16K | -4.4% | — |
| Jan 5, 2026 | Warmuth MarkusPresident & CEO · O·D | ▼ Sale | 10,135 | $15.17 | $154K | -1.6% | — |
| Jan 5, 2026 | Janku FilipChief Medical Officer · O | ▼ Sale | 3,155 | $15.17 | $48K | -4% | — |
| Jan 5, 2026 | Townson SharonChief Scientific Officer · O | ▼ Sale | 3,155 | $15.17 | $48K | -4.4% | — |
Every $GLUE filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Monte Rosa Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $GLUE feed.